STAT
FEBRUARY 7, 2024
In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers. But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI?
PharmaVoice
FEBRUARY 9, 2024
After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ALiEM - Pharm Pearls
FEBRUARY 5, 2024
Welcome to the AIR Toxicology Module! After carefully reviewing all relevant posts in the past 12 months from the top 50 sites of the Digital Impact Factor [1], the ALiEM AIR Team is proud to present the highest quality online content related to related to toxicology in the Emergency Department. 8 blog posts met our standard of online excellence and were approved for residency training by the AIR Series Board.
The Pharmacist
FEBRUARY 7, 2024
Using Additional Roles Reimbursement Scheme (ARRS) funding for GPs would be ‘ridiculous’ given the difficulty of recruiting doctors and the efficiency of utilising other roles within the surgery, a pharmacist partner in a south coast general practice has said. Shilpa Patel, lead prescribing pharmacist and partner at WellBN health centre in Brighton and Hove, spoke […] The post Adding GPs to ARRS not the way forward, says pharmacist partner appeared first on The Pharmacist.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 5, 2024
The prediction is dire: Cancer cases around the world are expected to surge 77% by 2050, a new report from the World Health Organization estimates. That attention-grabbing statistic, based on an analysis of 185 countries, cites a growing, aging population and factors including tobacco, alcohol, obesity, and pollution. Perhaps the most damning part of the report reveals the disparities determined by income.
PharmaVoice
FEBRUARY 6, 2024
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Pharmacist
FEBRUARY 8, 2024
Nearly 70% of the public would be happy for their medical records to be shared between clinicians, a YouGov poll for The Times Health Commission has found. Its report, published this week, proposed patient record sharing through digital ‘patient passports’ and incentivising pharmacists ‘to do more prescribing, consultations and community care’ to relieve pressure on […] The post Seven in 10 back data sharing between clinicians appeared first on The Pharmacist.
STAT
FEBRUARY 3, 2024
Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes. Beginning in 2018, Juul executives, including the company’s CEO, discussed six- and seven-figure partnerships with civil rights organizations, one of which would have seen it send as much as $7 million to Sharpton’s group, according to internal emails and documents that were released this week as par
PharmaVoice
FEBRUARY 6, 2024
The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.
Pharmaceutical Technology
FEBRUARY 6, 2024
The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Pharmacist
FEBRUARY 9, 2024
Pharmacist access to patient records is ‘more urgent than ever’, Royal Pharmaceutical Society (RPS) director for Scotland Laura Wilson will tell new health secretary Neil Gray. This comes as Mr Gray replaces former cabinet secretary for NHS recovery, health and social care Michael Matheson, who resigned yesterday following an investigation into data roaming charges he […] The post Call for patient records access as new Scottish ministers appointed appeared first on The Pharmacist.
STAT
FEBRUARY 5, 2024
Katie Keim was diagnosed with type 1 diabetes in 1967 when she was eight, well before the era of insulin pumps or even reliable home testing. The condition started eating away at her vision 20 years later. By the time she was 36, her sight was completely gone. Keim had lived an independent life as a child despite her illness. Her summers were spent exploring oceans with her family, not at diabetic summer camps.
Express Pharma
FEBRUARY 6, 2024
Rx Propellant (RxP), a platform focused on providing real estate solutions, including research and development (R&D) laboratories and associated facilities for the life sciences and associated sectors in India, has announced an initial investment of $75 million in phase 1 of the Navi Mumbai Research (NMR) District, as part of its continued regional expansion strategy across India.
FDA Law Blog: Biosimilars
FEBRUARY 7, 2024
By John A. Gilbert — Last week, DEA and DOJ announced a $59 million civil penalty settlement with eBay related to the failure to comply with Controlled Substances Act (CSA) requirements for identifying purchasers, maintaining records, and filing reports of individuals selling/purchasing pill presses and encapsulating machines. As stated in the press release , this was the fourth largest civil penalty settlement under the CSA and, ironically, did not involve the sale or distribution of any contr
The Pharmacist
FEBRUARY 5, 2024
The last 12 months have seen a marked increase in patients declining prescription medication because of cost, according to new research. The findings have subsequently sparked fresh calls for prescription charges to be reviewed or abolished. A survey of 1,357 pharmacists in England found that 97% had encountered patients foregoing some of the medicines on […] The post Pharmacists report rise in patients unable to collect prescriptions due to cost appeared first on The Pharmacist.
STAT
FEBRUARY 8, 2024
People receiving a double dose of naloxone are no more likely to survive an opioid overdose than people receiving a standard, 4-milligram nasal spray, according to a new study. The new paper , published Thursday in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, showed no significant difference in survival rates between people who were revived using 4- and 8-milligram sprays of naloxone, commonly known by the brand name Narcan.
pharmaphorum
FEBRUARY 8, 2024
Explore the commercial research landscape in the UK and the evolution of the National Institute for Health Research (NIHR) through an informative webinar.
BioPharma Dive
FEBRUARY 5, 2024
The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.
The Pharmacist
FEBRUARY 5, 2024
Pharmacies currently providing the Covid-19 vaccine are being asked by NHS England (NHSE) to extend their service provision contracts until 31 August 2024. The extension covers a potential spring booster programme, with the Joint Committee on Vaccination and Immunisation (JCVI) set to publish their guidance soon. While the fee for the extension period remains at […] The post Covid-19 vaccine contract extensions to carry added spring payment appeared first on The Pharmacist.
STAT
FEBRUARY 5, 2024
After a months-long fight with Texas Medicaid over coverage of a gene therapy, Afghan refugees now have a chance to save their infant son. After initially balking , Texas officials have agreed to pay for the costly treatment, the boy’s family and his doctor told STAT. At the end of last week, N. Pashai’s cell phone rang. It was from a Minnesota area code.
pharmaphorum
FEBRUARY 5, 2024
Data science in healthcare is transforming the industry, from drug discovery to patient care. Learn about the role of data, artificial intelligence (AI), and the impact of initiatives like the NHS Datastore in revolutionising healthcare outcomes.
BioPharma Dive
FEBRUARY 8, 2024
The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, will give it licensing opportunities and access to supply infrastructure.
The Pharmacist
FEBRUARY 5, 2024
Illegally traded medicines with a street value of more than £30m were seized by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2023. The seizures were made as part of an international initiative called Operation Pangea and accounted for more than 15.5 million doses. Among the illegally traded medicines were prescription-only anti-anxiety medication, opioids […] The post More than 15.5 million doses of illegal medicines seized in 2023 appeared first on The Pharmacist.
STAT
FEBRUARY 5, 2024
Amgen is trying a unique strategy with its obesity drug candidate: testing whether it can wean patients toward lower or less frequent doses over time. Very early data hints that Amgen’s candidate, called MariTide, may provide longer-lasting weight loss than highly popular obesity drugs on the market like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
pharmaphorum
FEBRUARY 9, 2024
Learn how implementing a SMART approach in stem cell manufacturing can lead to improved efficiency and cost reduction for the production of mesenchymal stem cells (MSCs) used in the treatment of osteoarthritic and autoimmune conditions.
Pharmaceutical Commerce
FEBRUARY 6, 2024
A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?
Pharma Times
FEBRUARY 5, 2024
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
STAT
FEBRUARY 7, 2024
Fatigue leads the list of persistent problems experienced by people with long Covid — which is why patients have pushed back against treatment approaches that endorse escalating levels of exercise for a condition that researchers are still trying to understand. They fear post-exertional malaise, the debilitating price to be paid for pushing their bodies too hard.
pharmaphorum
FEBRUARY 8, 2024
Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.
BioPharma Dive
FEBRUARY 5, 2024
In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.
FDA Law Blog: Biosimilars
FEBRUARY 9, 2024
By Adrienne R. Lenz, Principal Medical Device Regulation Expert & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — As an end of the year gift, FDA finalized its guidance document, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations , in late December. We previously blogged on the draft guidance ( here ) and on FDA’s broader framework for Digital Health Technologies (DHT) ( here and here ).
STAT
FEBRUARY 5, 2024
LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs. Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.
pharmaphorum
FEBRUARY 9, 2024
The combination of drugs for hypertension and software to personalise dosing to an individual patient has been shown to deliver improved blood pressure control and adherence to therapy in a pilot study.
Pharmaceutical Commerce
FEBRUARY 9, 2024
Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so.
Express Pharma
FEBRUARY 8, 2024
Biocon Biologics announced a five-year partnership with Sandoz AG which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD $35 million) and biosimilar Bevacizumab (market value of AUD $45 million) in Australia. Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pha
Expert insights. Personalized for you.
361 
Let's personalize your content